Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy

Title:Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy

Volume: 22 Issue: 16

Author(s): Dariusz Rakus, James A. McCubrey, Stephen L. Abrams, Zoya Demidenko, Agustino Tafuri, Michelle Milella, Melchiorre Cervello, Giuseppe Montalto, Danijela Maksimovic-Ivanic, Sanja Mijatovic, Joerg Basecke, Joanna Dulinska-Litewka, Piotr Laidler, Agnieszka Gizak, Linda S. Steelman, Lyudmyla Drobot, Concettina Fenga, Aurora Scalisi, Ferdinando Nicoletti, Saverio Candido, Massimo Libra, Sandra Marmiroli, Luca M. Neri, Alberto M. Martelli, Matilde Y. Follo, Lucio Cocco, Kvin Lertpiriyapong and Timothy Fitzgerald

Affiliation:

Keywords: EGFR, HER2, mIRs, Cancer Stem Cells, Drug Resistance, Metastasis.

Abstract: The roles of the epidermal growth factor receptor (EGFR) signaling pathway in various cancers including breast, bladder, brain, colorectal, esophageal, gastric, head and neck, hepatocellular, lung, neuroblastoma, ovarian, pancreatic, prostate, renal and other cancers have been keenly investigated since the 1980’s. While the receptors and many downstream signaling molecules have been identified and characterized, there is still much to learn about this pathway and how its deregulation can lead to cancer and how it may be differentially regulated in various cell types. Multiple inhibitors to EGFR family members have been developed and many are in clinical use. Current research often focuses on their roles and other associated pathways in cancer stem cells (CSCs), identifying sites where therapeutic resistance may develop and the mechanisms by which microRNAs (miRs) and other RNAs regulate this pathway. This review will focus on recent advances in these fields with a specific focus on breast cancer and breast CSCs. Relatively novel areas of investigation, such as treatments for other diseases (e.g., diabetes, metabolism, and intestinal parasites), have provided new information about therapeutic resistance and CSCs.

Cite this article as:

Rakus Dariusz, McCubrey A. James, Abrams L. Stephen, Demidenko Zoya, Tafuri Agustino, Milella Michelle, Cervello Melchiorre, Montalto Giuseppe, Maksimovic-Ivanic Danijela, Mijatovic Sanja, Basecke Joerg, Dulinska-Litewka Joanna, Laidler Piotr, Gizak Agnieszka, Steelman S. Linda, Drobot Lyudmyla, Fenga Concettina, Scalisi Aurora, Nicoletti Ferdinando, Candido Saverio, Libra Massimo, Marmiroli Sandra, Neri M. Luca, Martelli M. Alberto, Follo Y. Matilde, Cocco Lucio, Lertpiriyapong Kvin and Fitzgerald Timothy, Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy, Current Pharmaceutical Design 2016; 22 (16) . https://dx.doi.org/10.2174/1381612822666160304151011